Mithra Pharmaceuticals S.A.
MITPF · OTC
12/31/2023 | 6/30/2023 | 12/31/2022 | 6/30/2022 | |
|---|---|---|---|---|
| Revenue | $33,120 | $7,035 | $55,640 | $11,357 |
| % Growth | 370.8% | -87.4% | 389.9% | – |
| Cost of Goods Sold | $19,579 | $14,585 | $18,653 | $12,910 |
| Gross Profit | $13,541 | -$7,550 | $36,987 | -$1,553 |
| % Margin | 40.9% | -107.3% | 66.5% | -13.7% |
| R&D Expenses | $30,784 | $32,386 | $36,523 | $27,518 |
| G&A Expenses | $14,887 | $7,198 | $7,633 | $7,042 |
| SG&A Expenses | $9,904 | $2,238 | $2,436 | $2,399 |
| Sales & Mktg Exp. | $1,077 | $1,194 | $915 | $1,185 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $41,188 | $34,624 | $38,959 | $29,917 |
| Operating Income | -$27,647 | -$42,174 | -$1,972 | -$31,470 |
| % Margin | -83.5% | -599.5% | -3.5% | -277.1% |
| Other Income/Exp. Net | -$82,713 | -$9,761 | $18,363 | $1,518 |
| Pre-Tax Income | -$110,360 | -$51,935 | $16,391 | -$29,952 |
| Tax Expense | $12,673 | -$1,466 | $44,764 | $1,295 |
| Net Income | -$123,033 | -$50,469 | -$28,373 | -$31,247 |
| % Margin | -371.5% | -717.4% | -51% | -275.1% |
| EPS | -1.78 | -0.88 | -0.52 | -0.69 |
| % Growth | -102.3% | -69.2% | 24.6% | – |
| EPS Diluted | -1.78 | -0.88 | -0.52 | -0.69 |
| Weighted Avg Shares Out | 69,124 | 57,097 | 54,402 | 45,043 |
| Weighted Avg Shares Out Dil | 69,124 | 57,097 | 54,402 | 45,043 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,004 | $741 | $5,690 | $489 |
| Interest Expense | $11,886 | $11,013 | $15,784 | $7,638 |
| Depreciation & Amortization | $6,060 | $6,154 | $6,112 | $5,828 |
| EBITDA | -$18,707 | -$34,064 | $7,404 | -$21,710 |
| % Margin | -56.5% | -484.2% | 13.3% | -191.2% |